Wiley Blackwell

SHERPA: Unknown

People

  1. Herr
    Herr
  2. Brennan
    Brennan
  3. Motzer
    Motzer
  4. Shah
    Shah
  5. Danishefsky
    Danishefsky
  6. Russo
    Russo
  7. Shaha
    Shaha
  8. Vickers
    Vickers
  9. Eastham
    Eastham
  10. Mulhall
    Mulhall

Groups

  1. Department of Medicine (1520)
  2. Surgery (1224)
  3. Solid Tumor Oncology Division (883)
  4. Survivorship Research (806)
  5. GSK Faculty (664)
  6. Sloan Kettering Institute Faculty (622)
  7. Population Sciences Research Program (614)
  8. Department of Pathology and Laboratory Medicine (533)
  9. Epidemiology and Biostatistics (484)
  10. Center for Hematologic Malignancies (432)
Search Within
Formats
  1. Journal Article (3486)
  2. Meeting Abstract (680)
  3. Review (197)
  4. Conference Paper (94)
  5. Book Section (91)
  6. Editorial (90)
  7. Research Letter (34)
  8. Correspondence (25)
  9. Guidelines (23)
  10. Miscellaneous (6)
  11. Book Whole (3)
Groups
  1. Department of Medicine (1520)
  2. Surgery (1224)
  3. Solid Tumor Oncology Division (883)
  4. Survivorship Research (806)
  5. GSK Faculty (664)
  6. Sloan Kettering Institute Faculty (622)

More Groups

People
  1. Harry Herr (91)
  2. Murray Brennan (86)
  3. Robert Motzer (86)
  4. Jatin Shah (77)
  5. Samuel Danishefsky (74)
  6. Ashok Shaha (71)

More People

Years
  1. 2025 (80)
  2. 2024 (195)
  3. 2023 (264)
  4. 2022 (187)
  5. 2021 (221)
  6. 2020 (183)

More Years

Publications
  1. Cancer (1449)
  2. Journal of Surgical Oncology (368)
  3. BJU International (332)
  4. Hematological Oncology (199)
  5. Histopathology (151)
  6. EMBO Journal (131)

More Publications

Results (4729)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Enhancing T‐cell responses to GCB‐like lymphomas with immune‐checkpoint‐blockade‐based therapies
    Meeting Abstract

    Serganova, I.; Bucktrout, R.; Isshiki, Y.; Sarapulov, A.; Santella, A.; Rodriguez, M.; Chakraborty, S.; Brunschvig, S.; Qualls, D.; Vardhana, S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (LISO‐CEL) versus standard of care (SOC) as second‐line therapy in large B‐cell lymphoma (TRANSFORM study): Subgroup analyses by prior therapy response
    Meeting Abstract

    Nastoupil, L. J.; Kamdar, M.; Chavez, J. C.; Ghesquieres, H.; Ghosh, M.; Holmes, H.; López‐Guillermo, A.; Martínez‐López, J.; Novak, U.; Ribrag, V.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (LISO‐CEL) versus standard of care (SOC) as second‐line therapy in large B‐cell lymphoma (TRANSFORM study): Subgroup analyses by prior therapy response
    Meeting Abstract

    Tobin, J. W.; Jurinovic, V.; Tsang, H.; Roos, D.; Tsang, R.; Macann, A.; Davis, S.; Christie, D.; Law, S.; Nath, K.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Very low dose radiation therapy for indolent lymphoma: Comparing "Big Boom" (4GY × 1) versus "Boom Boom" (2GY × 2)
    Meeting Abstract

    Hajj, C.; Lee, J.; Boe, L.; Fregonese, B.; Lebow, E.; Wijetunga, N. A.; Hubbeling, H.; Tringale, K.; Freret, M.; Imber, B.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • AFM13 in patients with CD30 positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL): Results from the phase 2 redirect study
    Meeting Abstract

    Kim, W. S.; Shortt, J.; Zinzani, P. L.; Mikhaylova, N.; Marin‐Niebla, A.; Radeski, D.; Ribrag, V.; Domenech, E. D.; Sawas, A.; Alexis, K.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Impact of response to systemic bridging therapy on clinical outcomes and cytokine profile in patients receiving CAR T‐cell therapy for aggressive B‐cell lymphoma
    Meeting Abstract

    Wills, B.; Shouval, R.; Flynn, J.; Devlin, S. M.; Shah, G. L.; Scordo, M.; Dahi, P. B.; Lin, R. J.; Imber, B.; Parascondola, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • BRCA1/2 mutations impact on the development of breast implant‐associated lymphoma (BIA‐ALCL) in women with breast cancer reconstructed with textured breast implants
    Meeting Abstract

    Ghione, P.; Arcila, M.; Joseph, V.; Dogan, A.; Cordeiro, P.; Salles, G.; de Jong, D.; Horwitz, S.; Mandelker, D.; van Leeuwen, F.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • High complete metabolic response rates with epcoritamab + R‐CHOP in previously untreated (1L) high‐risk DLBCL, including double‐hit/triple‐hit: EPCORE NHL‐2 update
    Meeting Abstract

    Falchi, L.; Clausen, M. R.; Offner, F.; de Vos, S.; Brody, J.; Linton, K. M.; Snauwaert, S.; Cordoba, R.; Wu, J.; Bykhovski, I.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Chromatin accessibility profiling to increase diagnostic accuracy and refine cell‐of‐origin classification of mature T‐cell lymphomas
    Meeting Abstract

    Julia, E.; Mareschal, S.; Chebel, A.; Camille, G.; Missaglia, E.; Rattina, V.; Lours, C.; Testard, Q.; Tschantz, M.; Sebai, S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save